ADAM17在动脉粥样硬化发病机制中作用的研究进展

Research progress on the role of ADAM17 in the pathogenesis of atherosclerosis

动脉粥样硬化是一种慢性炎性反应疾病,涉及脂质代谢失衡和免疫反应失调。去整合素-金属蛋白酶17(ADAM17)是经典的膜蛋白脱落酶,通过参与炎性反应、病理性血管生成及斑块不稳定过程,促进动脉粥样硬化的发生发展。在少数情况下,ADAM17也表现出抗动脉粥样硬化作用。因此,关注ADAM17在动脉粥样硬化中的作用机制,有利于对动脉粥样硬化诊断及其治疗提供新见解。

Atherosclerosis is a kind of chronic inflammatory disease involving imbalance of lipid metabolism and immune disorders.The disintegrin metalloprotease 17(ADAM17)is a classic membrane protein shedding enzyme,which promotes atherosclerosis by participating in the process of inflammatory response,angiogenesis and plaque instability.In a few cases,ADAM17 also exhibits anti-atherosclerotic effects.Therefore,paying attention to the mechanism of ADAM17 in atherosclerosis will help to provide new insights into the diagnosis and treatment of atherosclerosis.